Overview

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.
Phase:
Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer